Heron Therapeutics (HRTX) Convertible Debt (2021 - 2025)
Historic Convertible Debt for Heron Therapeutics (HRTX) over the last 6 years, with Q3 2025 value amounting to $32.2 million.
- Heron Therapeutics' Convertible Debt fell 7849.87% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year decrease of 7849.87%. This contributed to the annual value of $149.7 million for FY2024, which is 14.05% up from last year.
- Latest data reveals that Heron Therapeutics reported Convertible Debt of $32.2 million as of Q3 2025, which was down 7849.87% from $149.8 million recorded in Q1 2025.
- Heron Therapeutics' Convertible Debt's 5-year high stood at $149.8 million during Q1 2025, with a 5-year trough of $32.2 million in Q3 2025.
- For the 5-year period, Heron Therapeutics' Convertible Debt averaged around $142.5 million, with its median value being $149.3 million (2023).
- Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Convertible Debt was 14.11% (2025), while the steepest drop was 7849.87% (2025).
- Heron Therapeutics' Convertible Debt (Quarter) stood at $149.1 million in 2021, then grew by 0.14% to $149.3 million in 2022, then grew by 0.14% to $149.5 million in 2023, then grew by 0.14% to $149.7 million in 2024, then tumbled by 78.51% to $32.2 million in 2025.
- Its Convertible Debt was $32.2 million in Q3 2025, compared to $149.8 million in Q1 2025 and $149.7 million in Q4 2024.